POMC: The Precursor Behind Your Appetite Control

Setmelanotide and MC4R

241 amino acids

POMC is a 241-amino acid precursor protein that gets cut into at least 10 biologically active peptides, including alpha-MSH, the primary appetite-suppressing signal in the melanocortin pathway.

Baldini & Bhatt, Journal of Endocrinology, 2019

Baldini & Bhatt, Journal of Endocrinology, 2019

View as image

One gene produces a single large protein. That protein gets cut into more than 10 different peptide hormones, each with distinct functions spanning appetite control, stress response, pain modulation, skin pigmentation, and immune regulation. The gene is POMC (proopiomelanocortin), and the peptides it produces are among the most important signaling molecules in human physiology. When POMC mutations prevent normal processing, the result is severe early-onset obesity, adrenal insufficiency, and red hair. The discovery of the melanocortin pathway, from POMC through alpha-MSH to MC4R activation, has reshaped how researchers understand appetite regulation and has produced the first FDA-approved treatment specifically targeting genetic obesity: setmelanotide. For a complete overview of that drug and its receptor target, see Setmelanotide: The MC4R Agonist for Rare Genetic Obesity Syndromes.

What POMC Is: One Protein, Many Peptides

Proopiomelanocortin (POMC) is a 241-amino acid polypeptide encoded by the POMC gene on chromosome 2. It is not itself a hormone. It is a precursor, a biological raw material that gets enzymatically cut into smaller, active peptide hormones after it is produced.

The name itself reveals the history of its discovery. "Pro" indicates it is a precursor. "Opio" refers to opioid peptides (beta-endorphin). "Melano" refers to melanocyte-stimulating hormones (MSH). "Cortin" refers to adrenocorticotropic hormone (ACTH), which stimulates the adrenal cortex. Researchers originally studying these three separate peptide families realized they all came from the same precursor protein.

POMC is primarily expressed in two locations: corticotroph cells of the anterior pituitary gland and neurons in the arcuate nucleus of the hypothalamus. It is also expressed at lower levels in the nucleus tractus solitarius of the brainstem, in skin keratinocytes, and in immune cells. Ronnekleiv and colleagues (2025) characterized the early development of hypothalamic neurons expressing POMC, showing that these neurons establish their identity and connectivity during fetal development, with implications for how early-life nutritional environments might shape lifelong appetite regulation.^[8]

How POMC Gets Cut: Tissue-Specific Processing

The peptides produced from POMC depend entirely on which enzymes are present in the cell doing the cutting. This is called tissue-specific processing, and it is the reason the same POMC precursor produces different hormones in different parts of the body.

In the anterior pituitary (corticotroph cells), the predominant enzyme is prohormone convertase 1/3 (PC1/3). PC1/3 cleaves POMC at specific pairs of basic amino acids, producing:

• ACTH (adrenocorticotropic hormone, 39 amino acids), which travels to the adrenal glands and stimulates cortisol production
• Beta-lipotropin (beta-LPH), a 91-amino acid fragment with roles in lipid metabolism

In the hypothalamus and intermediate pituitary, both PC1/3 and PC2 are present. PC2 performs additional cleavages that PC1/3 cannot, producing:

• Alpha-MSH (alpha-melanocyte stimulating hormone, 13 amino acids), the primary anorexigenic (appetite-suppressing) peptide in the brain
• Beta-MSH and gamma-MSH, which also bind melanocortin receptors
• Beta-endorphin (31 amino acids), an endogenous opioid peptide involved in pain modulation and reward
• CLIP (corticotropin-like intermediate lobe peptide)

A 2025 study by Yamamoto and colleagues revealed that POMC processing also occurs extracellularly, generating a shortened form of beta-endorphin that regulates behavior differently from the full-length peptide. This finding expanded the understanding of POMC processing beyond the classical intracellular pathway.^[9]

The tissue-specific processing means that a mutation in POMC affects multiple hormone systems simultaneously. Loss of POMC eliminates alpha-MSH (causing obesity and pigmentation changes), ACTH (causing adrenal insufficiency), and beta-endorphin (affecting pain and reward processing) all at once.

Alpha-MSH and Appetite: The Melanocortin Pathway

The most studied role of POMC in appetite regulation centers on alpha-MSH and the melanocortin pathway. Baldini and Bhatt published a comprehensive 2019 review of this pathway, summarizing decades of research into how melanocortins control food intake and energy expenditure.^[1]

The circuit works like this: when energy stores are adequate (signaled by leptin from fat tissue and insulin from the pancreas), POMC neurons in the arcuate nucleus become active. They release alpha-MSH, which binds to melanocortin 4 receptors (MC4R) on second-order neurons in the paraventricular nucleus. MC4R activation suppresses appetite and increases energy expenditure through effects on sympathetic nervous system output and thyroid hormone regulation.

Simultaneously, a parallel set of neurons in the arcuate nucleus (AgRP/NPY neurons) opposes the POMC system. AgRP (agouti-related peptide) is an endogenous MC4R antagonist: it blocks the receptor, preventing alpha-MSH from activating it. NPY (neuropeptide Y) acts through its own receptors to stimulate appetite. When energy stores are low (low leptin, low insulin), AgRP/NPY neurons become active and POMC neurons are suppressed, creating hunger. For more on this opposing system, see AgRP: The Peptide That Makes You Hungry by Blocking MC4R.

Possa-Paranhos and colleagues (2025) demonstrated that MC3R (melanocortin 3 receptor), a less-studied melanocortin receptor, plays a distinct role in this system. MC3R signaling in the medial hypothalamus regulates energy rheostasis, the process by which the body defends a particular body weight setpoint, rather than acute meal-to-meal appetite control.^[10]

What Happens When POMC Fails: Genetic Obesity

Mutations that disrupt POMC production or processing cause one of the most severe forms of genetic obesity. Humans with biallelic loss-of-function POMC mutations develop a characteristic triad: severe early-onset obesity (typically appearing in the first year of life), adrenal insufficiency (from ACTH deficiency), and altered skin/hair pigmentation (from alpha-MSH deficiency, often resulting in red hair in individuals of European ancestry).

The obesity is driven by the complete absence of alpha-MSH signaling at MC4R. Without this brake on appetite, affected individuals experience relentless hunger (hyperphagia) from infancy. Unlike common obesity, where the melanocortin pathway is present but overwhelmed, POMC deficiency represents a total loss of one of the brain's primary satiety circuits.

MC4R mutations produce a similar but less severe phenotype. MC4R deficiency is the most common monogenic cause of severe obesity, affecting an estimated 2-6% of individuals with severe early-onset obesity. Ayers and colleagues (2018) proposed a patient stratification framework for melanocortin pathway dysfunction, noting that the severity depends on whether the mutation causes complete or partial loss of MC4R signaling.^[3] Metzger and colleagues (2024) identified a specific human MC4R mutation that selectively disrupts Gq/11alpha signaling while preserving Gs signaling, leading to hyperphagia and obesity, suggesting that MC4R controls appetite through multiple intracellular pathways.^[4] For more on this receptor and its mutations, see MC4R: The Receptor Mutation That Causes Severe Childhood Obesity.

Setmelanotide: Replacing the Missing Signal

The discovery that POMC deficiency obesity is caused by the absence of alpha-MSH at MC4R led directly to a therapeutic strategy: provide an MC4R agonist to replace the missing signal. Setmelanotide (brand name Imcivree) is a synthetic cyclic peptide that binds and activates MC4R, mimicking the action of alpha-MSH.

Clement and colleagues (2020) published the pivotal trial results in The Lancet Diabetes & Endocrinology. In patients with POMC deficiency obesity, setmelanotide produced a mean body weight reduction of 25.6% over 52 weeks. In patients with LEPR (leptin receptor) deficiency, the mean reduction was 12.5%. Both groups experienced significant reductions in hunger scores.^[2] These results led to FDA approval in 2020, making setmelanotide the first treatment specifically targeting the molecular cause of genetic obesity.

Giannopoulou and colleagues (2026) published a multigenerational case study of MC4R deficiency, noting the variable expressivity of MC4R mutations across family members and the importance of genetic testing for early identification.^[11]

GLP-1 Drugs and the Melanocortin Circuit: Unexpected Connections

Recent research has revealed that GLP-1 receptor agonists (semaglutide, tirzepatide) interact with the melanocortin pathway in ways that were not anticipated when these drugs were developed for diabetes.

McMorrow and colleagues (2025) published in the Journal of Clinical Investigation that incretin receptor agonism rapidly inhibits AgRP neurons, the hunger-promoting counterpart to POMC neurons. This means GLP-1 drugs suppress appetite partly by silencing the melanocortin pathway's pro-hunger arm, not just through gut-level satiety mechanisms.^[6]

Bhatnagar and colleagues (2025) reported in Nature Medicine that tirzepatide produced weight reduction even in patients with MC4R deficiency, a population where the melanocortin pathway is broken. This suggests that GLP-1/GIP dual agonism can bypass the MC4R pathway to some degree, achieving weight loss through alternative circuits.^[5]

Hitaka and colleagues (2026) compared the efficacy of semaglutide, tirzepatide, and retatrutide in MC4R-deficient obese models, finding that multi-agonist peptides showed greater efficacy than single GLP-1 agonists in this context, possibly by engaging multiple parallel appetite-regulating pathways simultaneously.^[7]

These findings have practical implications. If a patient with genetic obesity due to a melanocortin pathway defect responds partially to GLP-1 drugs, combination therapy with setmelanotide (targeting MC4R directly) and a GLP-1 agonist (targeting alternative pathways) could theoretically provide additive or synergistic weight loss. Ashlaw and colleagues (2026) are exploring this concept with a monomeric peptide that simultaneously agonizes both MC4R and GLP-1R.^[12]

Beyond Appetite: POMC's Other Products

While appetite regulation receives the most attention, POMC-derived peptides serve critical functions across multiple organ systems.

ACTH and the stress response: ACTH released from the anterior pituitary is the primary driver of cortisol production. Without ACTH (as in POMC deficiency), the adrenal glands atrophy and cortisol production fails, a life-threatening condition requiring lifelong glucocorticoid replacement.

Beta-endorphin and pain/reward: Beta-endorphin is a potent endogenous opioid that modulates pain perception, stress responses, and reward circuits. POMC neurons in the arcuate nucleus release beta-endorphin alongside alpha-MSH, meaning that the same neurons that suppress appetite also engage the opioid reward system. This dual release may explain why eating provides both satiation (through alpha-MSH at MC4R) and pleasure (through beta-endorphin at opioid receptors).

Alpha-MSH and skin pigmentation: Alpha-MSH binds MC1R in melanocytes, stimulating eumelanin production (dark pigment). POMC deficiency results in reduced MC1R stimulation, often producing red hair and fair skin in affected individuals. This connection between appetite and pigmentation, mediated by different products of the same precursor, is one of the most striking examples of peptide hormone pleiotropy.

Alpha-MSH and immune function: Alpha-MSH has anti-inflammatory properties, suppressing the production of pro-inflammatory cytokines like IL-1, IL-6, and TNF-alpha. This immune-regulatory function means POMC-derived peptides participate in cross-talk between the neuroendocrine and immune systems.

The Bottom Line

POMC is a single precursor protein that produces more than 10 active peptides, including alpha-MSH (appetite suppression), ACTH (cortisol regulation), and beta-endorphin (pain modulation). Loss-of-function mutations cause severe early-onset obesity, adrenal insufficiency, and altered pigmentation. Setmelanotide, an MC4R agonist that replaces the missing alpha-MSH signal, produced 25.6% weight loss in POMC-deficient patients. Recent evidence shows GLP-1 drugs interact with the melanocortin pathway by inhibiting AgRP neurons, and multi-agonist peptides targeting both GLP-1R and MC4R represent the next frontier in genetic obesity treatment.

Frequently Asked Questions

What is POMC and what does it do?

POMC (proopiomelanocortin) is a 241-amino acid precursor protein produced mainly in the pituitary gland and hypothalamus. It is enzymatically cleaved into multiple active peptide hormones including alpha-MSH (which suppresses appetite), ACTH (which stimulates cortisol production), and beta-endorphin (which modulates pain). The specific peptides produced depend on which enzymes are present in the tissue processing the POMC protein.

What happens when the POMC gene is mutated?

Biallelic (both copies) loss-of-function POMC mutations cause a triad of severe early-onset obesity, adrenal insufficiency, and altered pigmentation (often red hair). The obesity results from loss of alpha-MSH signaling at MC4R in the hypothalamus. The adrenal insufficiency results from loss of ACTH. Affected children develop relentless hunger from infancy. Setmelanotide, an MC4R agonist approved in 2020, is the first targeted treatment for this condition.

How does alpha-MSH suppress appetite?

Alpha-MSH is released by POMC neurons in the arcuate nucleus of the hypothalamus when energy stores are adequate (signaled by leptin and insulin). It binds MC4R on neurons in the paraventricular nucleus, which suppresses food intake and increases energy expenditure through sympathetic nervous system activation. This signal is opposed by AgRP, which blocks MC4R to promote hunger. The balance between alpha-MSH and AgRP at MC4R determines appetite.

Is POMC deficiency the same as MC4R deficiency?

No. POMC deficiency eliminates the ligand (alpha-MSH) that activates MC4R, plus all other POMC-derived peptides (ACTH, beta-endorphin). MC4R deficiency is a mutation in the receptor itself. Both cause severe obesity through loss of melanocortin signaling, but POMC deficiency also causes adrenal insufficiency and pigmentation changes. MC4R deficiency is more common, affecting 2-6% of individuals with severe early-onset obesity.

Do GLP-1 drugs like semaglutide work through the POMC pathway?

Partially. McMorrow et al. (2025) showed that GLP-1 receptor agonists rapidly inhibit AgRP neurons, the hunger-promoting counterpart to POMC neurons in the melanocortin circuit. Bhatnagar et al. (2025) showed that tirzepatide can produce weight loss even in MC4R-deficient patients, suggesting GLP-1/GIP pathways can partially bypass the melanocortin circuit through alternative mechanisms.^[5][6]

What is setmelanotide and how does it treat POMC deficiency?

Setmelanotide (Imcivree) is a synthetic cyclic peptide that activates MC4R, mimicking the action of alpha-MSH. In POMC-deficient patients who lack alpha-MSH, setmelanotide replaces the missing signal. The pivotal trial showed 25.6% mean weight loss over 52 weeks, with significant hunger reduction. It was approved by the FDA in 2020 as the first treatment targeting the molecular cause of genetic obesity.^[2]